Released Feb 10, 2021, after the close
10-K filed Feb 25, 2021, 56 days after period end · 0001162194-21-000013
Q4 2020 · 10-K
Revenue$44.61M$44.61M +37.5% vs Q4 2019+11.9% vs Q3 2020
Net Income-$18.03M-$18.03M derivedN/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$0.24-$0.24 N/M vs Q4 2019N/M vs Q3 2020
Gross Profit$22,079,000+25.9%
Operating Incomederived-$16,904,000N/M
Operating Cash Flowderived-$3,733,000N/M
Free Cash Flowderived-$14,440,000N/M
Margins · derived
Gross margin49.5%−4.6 pt vs Q4 2019
Operating margin-37.9%−9.6 pt vs Q4 2019
Net margin-40.4%−1.3 pt vs Q4 2019
What the release said
The release
Same quarter
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $44.61M | $32.44M | $32.33M | $27.75M |
| Net Income | -$18.03M | -$12.69M | -$14.78M | -$10.46M |
| EPS Diluted | -$0.24 | -$0.18 | -$0.36 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR